FDA says marijuana has a legitimate medicinal purpose

Original Article ↗ Hacker News Discussion ↗

Medical and Symptomatic Uses (Especially Sleep and Pain)

  • Many report cannabis, especially edibles, as highly effective for insomnia, RLS, neuropathic pain, jet lag, anxiety, and general “racing mind” at bedtime.
  • Users describe dosing patterns (e.g., 20mg THC with CBN, indica-leaning products, THC+CBD flower) and costs ($150/month) as acceptable relative to the benefit of decent sleep.
  • Some find THC lets them “turn off thoughts” and even normalize sleep long-term after stopping. Others report improved dream experience and trauma-related sleep issues.
  • Comparisons with prescription meds (trazodone, quetiapine, benzos, z-drugs, antihistamines) highlight trade-offs: side effects, dependence, and less natural-feeling sleep.

Tolerance, Side Effects, and Risks

  • Tolerance buildup is common; some cycle between cannabis and prescription meds to reset.
  • Reported downsides: next-day cognitive fog, disrupted REM, poor sleep quality despite easier sleep onset, racing thoughts, anxiety, “the fear” (paranoia/agoraphobia), dependence concerns, nausea/CHS, reflux, and withdrawal-like sleep issues on stopping.
  • Multiple counter-anecdotes: cannabis worsens insomnia or does nothing short of very high doses.

Strains, Cannabinoids, and Dosing Nuance

  • Perceived differences between indica vs sativa, THC percentage, and cannabinoid/terpene “entourage” profiles.
  • Several note benefit from CBD and CBN combinations; high-CBD hemp mixed with THC is one strategy.
  • Emphasis that optimal dose and composition are highly individual and often require experimentation.

Legal Status, Scheduling, and Policy

  • Strong support for broad legalization and treating cannabis like other legal plants (kava, kratom, salvia), or like alcohol/tobacco.
  • Debate over U.S. scheduling: many see Schedule I status for cannabis, LSD, and psilocybin as absurd given emerging medical evidence; some expect rescheduling to Schedule III at most.
  • Discussion of harm-based vs “medical use”–based scheduling; calls for consistent inclusion of alcohol/tobacco.
  • Concerns that prohibition has stifled rigorous per-condition clinical trials and left users reliant on anecdotes.

Skepticism About the Reported FDA Shift

  • Some participants question whether the cited “FDA says…” claim is based on a new, official report, suggesting it may be misreporting or rehash of older HHS/DEA correspondence.